Following the introduction of alternative formulations of ciclosporin into the UK, please find below some materials that will help to communicate the potential complications that could result if a patient were inadvertently switched between ciclosporin brands.
These materials and the ESPRIT Group recommendations are aligned with the view of the British National Formulary (BNF):
“Patients should be stabilised on a single brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in bioavailability. Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient stabilised on one brand of ciclosporin to another brand, the patient should be monitored closely for side-effects, blood-ciclosporin concentration, and transplant function.”
Reference: British National Formulary (BNF). Accessed via BNF online, March 2010
A detailed review of the main issues and recommendations of the ESPRIT Group on the implications of substituting alternative formulations of ciclosporin from the one prescribed.
A summary of the main issues and recommendations of the ESPRIT Group on the implications of substituting alternative formulations of ciclosporin from the one prescribed.
A template letter to provide to patients, which outlines information on ciclosporin and the importance of not changing the brand they were originally prescribed without appropriate monitoring and surveillance.
A template letter to provide to your patients’ GPs, which highlights the importance of ensuring that a patient is maintained on the same formulation of ciclosporin that they were initiated on in the specialist unit. The letter also allows you to provide relevant emergency contact details.
The ESPRIT Group also provides printed treatment reminder cards to help educate patients on the importance of knowing which formulation of ciclosporin they have been prescribed. These can be ordered by clicking the ‘order’ button to the right, and filling out the form on the following page.
Should you have difficulty accessing these materials or require further information, please contact the ESPRIT Group Secretariat at email@example.com.